# US 2020/0371029 A1 · Automated immunoanalyzer system for performing diagnostic assays for autoimmune and infectious diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0371029 A1
- Document ID: US20200371029A1
- Status: Published application
- Kind: A1
- Application number: 16/940,947
- Filed: 2020-07-28
- Published: 2020-11-26
- Earliest claimed: 2013-03-15
- Assignees: Hycor Biomedical, Inc.
- Applicants: Hycor Biomedical, LLC
- Inventors: Mark David Van Cleve; Taylor Addison Reid; Linda Marie Trondle; Victoria Hung; Yi Luo; Dennis Edwin Rieger; Evan Phillip McMenamy; Nanditha Raghavan; Morkoah Blay Reliford; Douglas John Canfield; Elaine Grace Taine; Edsel Lawrence Noche Sinson; Scott William Vande Wetering; Teri Taylor; Travis Knox; Fran Zulo Cuaresma Jacaine; James Weston; Jennifer Bao-Guey Chan; Stephanie TuVi Ortega; Rachel Sarah Schell; Ronald Norman Diamond; Steven Michael Gann; Eric Darnell Hall; Tae Ho Hwang; John Lewis Morton; Anatoly Moskalev; Marinela Gombosev Stack; Bruce Alan Sargeant; Michelle Fredrika Forshager; Vanessa Camille Chua; Kylie Wilson
- Web page: https://patentgrep.com/patent/US20200371029A1

## CPC

- G01N 21/645: {Specially adapted constructive features of fluorimeters}
- G01N 21/274: {Calibration, base line adjustment, drift correction}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 21/76: Chemiluminescence; Bioluminescence
- G01N 33/5306: {Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding}
- G01N 33/54326: {Magnetic particles}
- G01N 33/5434: {using magnetic particle immunoreagent carriers which constitute new materials per se}
- G01N 33/54393: {Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/569: for microorganisms, e.g. protozoa, bacteria, viruses
- G01N 33/5695: {Mycobacteria}
- G01N 33/56983: {Viruses}
- G01N 33/582: {with fluorescent label}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 35/0098: {involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation (magnetic particles used in immunoassays G01N33/54326; magnetic separation in general B03C)}
- G01N 35/1011: {Control of the position or alignment of the transfer device}
- G01N 2021/6484: {Optical fibres}
- G01N 2035/0453: {Multiple carousels working in parallel}
- G01N 2035/1062: {for testing the liquid while it is in the transfer device}
- G01N 2201/0469: One cell, sequential, e.g. successive samples
- G01N 2201/062: LED's
- G01N 2201/0646: Light seals
- G01N 2201/08: Optical fibres; light guides
- G01N 2201/084: Fibres for remote transmission
- G01N 2201/12707: Pre-test of apparatus, e.g. dark test, sensor test
- G01N 2333/4703: Regulators; Modulating activity
- G01N 2333/62: Insulins
- G01N 2333/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
- G01N 2800/24: Immunology or allergic disorders
- Y10T 436/119163: with aspirator of claimed structure
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

A quantitative method for diagnosing an autoimmune disease or an infectious disease comprising performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex, wherein the capture reagent is a biotinylated autoantigen or infectious disease antigen; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.

## Claims

### Claim 1

A method of performing a diagnostic assay, comprising:
a) combining a capture reagent-coated separation medium, wherein the separation medium comprises fluorescently-labelled particles, with an analyte-containing sample in a reaction cuvette;
b) binding luminescent labels to the separation media in proportion to a number of bound analyte molecules, to form a complex;
c) measuring an initial fluorescent signal associated with an initial quantity of the fluorescently-labelled particles;
d) washing the complex;
e) adding a luminescing reagent or substrate to the cuvette to generate a luminescent signal in proportion to the number of bound analyte molecules,
f) measuring the luminescent signal and a final fluorescent signal associated with a final quantity of the fluorescently-labelled particles in the cuvette;
g) calculating a ratio of the final fluorescent signal to the initial fluorescent signal to obtain a bead retention ratio; and
h) adjusting a calibrated quantifiable response for bead retention by adjusting the luminescent signal by the bead retention ratio to calculate a reported value.

### Claim 2 (depends on 1)

The method of claim 1, wherein the fluorescently-labelled particles are magnetic.

### Claim 3 (depends on 1)

The method of claim 1, wherein the analyte-containing sample is a serum sample.

### Claim 4 (depends on 1)

The method of claim 1, wherein the analyte-containing sample is a plasma sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the capture reagent will be bound by analyte molecules in the analyte-containing sample.

### Claim 6 (depends on 6)

The method of claim 6, wherein the analyte molecules are capture reagent-specific immunoglobulins.

### Claim 7 (depends on 1)

The method of claim 1, wherein the binding of luminescent labels is mediated by a labeled anti-immunoglobulin conjugate.

### Claim 8 (depends on 7)

The method of claim 7, wherein the anti-immunoglobulin conjugate comprises horseradish peroxidase (HRP), Alkaline Phosphatase (ALP), or beta galactosidase (BGAL).

### Claim 9 (depends on 1)

The method of claim 1, wherein the fluorescently-labelled particles have been coated with streptavidin.

### Claim 10 (depends on 9)

The method of claim 9, wherein the capture reagent has been biotinylated and bound to the fluorescently-labelled particles through a biotin-streptavidin interaction.

### Claim 11 (depends on 6)

The method of claim 6, wherein the immunoglobulins are analyte-specific human immunoglobulin G (IgG).

### Claim 12 (depends on 6)

The method of claim 6, wherein the immunoglobulins are analyte-specific human immunoglobulin M (IgM).

### Claim 13 (depends on 6)

The method of claim 6, wherein the immunoglobulins are analyte-specific human immunoglobulin A (IgA)

### Claim 14 (depends on 6)

The method of claim 6, wherein the immunoglobulins are analyte-specific human immunoglobulin E (IgE).

### Claim 15 (depends on 1)

The method of claim 1, wherein binding luminescent labels to the separation media comprises incubating a labeled anti-immunoglobulin conjugate with the capture reagent-coated separation medium.

### Claim 16 (depends on 15)

The method of claim 15, wherein the conjugate is in a diluent including polyethylene glycol.

### Claim 17 (depends on 1)

The method of claim 1, wherein measuring the fluorescent signals and the luminescent signal takes place within an optics box.

### Claim 18 (depends on 1)

The method of claim 1, further comprising entering the fluorescence and luminescence measurements into an algorithm to generate a bead retention adjusted relative light unit signal.

### Claim 19 (depends on 18)

The method of claim 18, further comprising comparing the generated bead retention adjusted relative light unit signal to a calibration curve relative light unit signal.
